Avant Garde Clinical Research

06/25/2021

Dupilumab (Dupixent) is now approved to treat adults with chronic rhinosinusitis with nasal polyps. Practitioners should note the dose difference from treating asthma or atopic dermatitis (Aschenbrenner, 2019).
For complete prescribing information, go to:
www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf.
Reference:
Aschenbrenner, D.S. (2019). Dupilumab approved to treat chronic rhinosinusitis with nasal polyposis. The American Journal of Nursing Vol. 119 (10), pp. 21-22. Retrieved from https://eds-a-ebscohost-com.chamberlainuniversity.idm.oclc.org/eds/detail/detail?vid=7&sid=f90a6a78-0fe5-425e-bab0-5ebf156a2efc%40sessionmgr4008&bdata=JnNpdGU9ZWRzLWxpdmUmc2NvcGU9c2l0ZQ%3d%3d =31567245&db=cmedm

06/19/2021

From our fathers, we inherited many of the characteristics that make us unique. Many lucky people also inherited the ways we interact with others and view the world. There are also no biological fathers who deserve recognition on this special occasion and every day.

I want to honor the life of one of these excellent fathers I had the privilege to meet and get inspired by, Dr. Gustavo Victoriano Gonzales Sierra, an eminent scientist that left us recently after a life of contribution to clinical research.

I also want to congratulate my husband, an excellent, loving father and role model in my family.
We want to celebrate fatherhood today!

To All the great men that made a difference in our life: Happy fathers day from AvantGarde Clinical Research!

06/19/2021

Research always matters! Let us keep the good work and enjoy the following JAMA article.
AvantGarde Clinical Research

This randomized clinical trial assesses the effect of intravenous eptinezumab vs placebo on times to headache pain freedom and absence of most bothersome symptom (nausea, photophobia, or phonophobia) among patients experiencing a moderate to severe migraine attack.

06/10/2021

We are pleased to share this hopeful news about Alzheimer's treatment. Coincidentally, we posted on the same topic and the need for more compassionate research the same day of the approval announcement of this new treatment.
Enjoy the message:

(...) On Monday, the FDA announced the historic fast-tracked approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease. This is the first drug to target the pathophysiology of Alzheimer’s and significantly reduce amyloid-beta plaque in patients.

There has not been an FDA-approved treatment for the disease since 2003, and we are tremendously delighted by this news.

Read FDA Press Release
MoCA Research & Innovation has been working with Biogen and other major pharma to test and validate treatment options –such as Aducanumab—and facilitate rapid comprehensive screening of MCI and early-stage Alzheimer’s among large populations.

Early detection of MCI/Alzheimer’s is imperative to ensure optimal management and outcome. And now, with novel treatments, the progression of symptoms and disease conditions can be reduced or halted.

MoCA’s mission has always been to provide the most efficient assessment solutions for the earliest diagnosis of MCI, and we are excited to share with you soon the most advanced versions we are working on.

Cheers to you, the medical community (...).

Let us keep the good work!

AvantGarde Clinical Research

06/08/2021

There is not an entirely effective treatment for Alzheimer's disease at the moment. Research is the way to find the right cure.
Let us work with hope and passion.